Quarterly report
Open the filing on sec.gov
Kalaris Therapeutics, Inc. (KLRS)
Nasdaq: KLRS · Biological Products, (No Diagnostic Substances) · Berkeley Heights, NJ · filing with the SEC since 2018
The companyfiscal 2019, as filed
Revenue$165,000
Net income-$23.8M
Earnings per sharen/a
Operating cash flow-$20.2M
Cash$61.1M
Debtn/a
Shareholders’ equity-$51.5M-68.2%
Shares, dilutedn/a
Return on equity-55.1%
The recordfrom its filings
Filings in 202652
Newest filingNov 10 · 10-Q
Annual reportMar 17, 2026
Quarterly reportNov 10, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted1
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Net income -$43.4MCash from operations -$40.2Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Results released
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider holding, initial
Open the filing on sec.gov
Insider holding, initial
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.